| Today’s Big NewsSep 13, 2024 |
| By Kevin Dunleavy The day after Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.S. nod for its under-the-skin formulation of mega-blockbuster multiple sclerosis drug Ocrevus. The approval gives patients a more convenient injected way to receive Ocrevus as opposed to the infused formulation. |
|
|
|
By James Waldron It’s a busy Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapeutics all going public. |
By Conor Hale James Porter serves as medical director of robotic surgery at the Providence Swedish health system in Seattle. |
By Nick Paul Taylor Two senators want to empower the FDA to send warning letters to influencers and telehealth companies that publish deceptive drug ads online and require drugmakers to report payments to social media stars. |
|
Still Time to Shine! Submission deadline for the Fierce Life Sciences Innovation Awards have been extended to September 12. Click to submit your entry and learn more about what winner's will receive. 
|
|
By Kevin Dunleavy Using the ESMO Magnitude of Clinical Benefit Scale, a group of Harvard researchers has scored companies according to the value of the cancer drugs they have brought to the market. Among the standout drugmakers in the analysis were Novartis, Daiichi Sankyo and AstraZeneca. |
By Darren Incorvaia Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule BLX-7006 reduced the weight of obese mice by 15% over a 28-day span. |
By Darren Incorvaia In the wake of a second quarter that saw revenues decline by 3.2%, contract research organization Charles River Laboratories is laying off 3% of its workforce, a spokesperson confirmed to Fierce Biotech in an emailed statement. |
By Nick Paul Taylor Tonix Pharmaceuticals is trying to start a conversation about a potential shortcoming of oral migraine drugs, kicking off a national campaign to raise awareness of a condition that can affect absorption. |
By Darren Incorvaia,Zoey Becker After 25 years at Johnson & Johnson and 30 in the industry, Lucinda Warren is moving on to new pastures at Cue Biopharma as its first chief business officer. |
By Zoey Becker The under-the-skin formulation trims administration time down to seven minutes compared to the 30 to 60 minutes needed for intravenous Tecentriq. |
By Nick Paul Taylor The FDA should be more open and collaborative to unleash a surge in approvals of rare disease drugs, according to a report by the National Academies of Sciences, Engineering, and Medicine. |
By Angus Liu AstraZeneca is detailing Truqap's pivotal trial flop in triple-negative breast cancer, a result that could raise additional doubts around the first-in-class AKT inhibitor. From AZ's perspective, a company executive argued the failure was probably a one-off. |
By Darren Incorvaia Four years after launching a remote-controlled robotic laboratory in San Diego, Eli Lilly is shipping the operation overseas. The Big Pharma is selling a majority of the Life Sciences Studio laboratory to Arctoris, a contract research organization with headquarters in Oxford, England and Boston. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," we’re looking at what goes into manufacturing and supply of flu vaccines. |
|
|---|
|
|
|
Bringing new oncology therapies to market is challenging, but novel, safer treatments are needed. Download the new QPS Oncology white paper to learn more about oncology clinical trials, challenges and solutions. .png)
|
|
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
